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The possibility of using computer simulation and mathematical modeling to gain insight into biological and other
complex systems is receiving increased attention. However, it is as yet unclear to what extent these techniques will
provide useful biological insights or even what the best approach is. Epstein–Barr virus (EBV) provides a good
candidate to address these issues. It persistently infects most humans and is associated with several important
diseases. In addition, a detailed biological model has been developed that provides an intricate understanding of EBV
infection in the naturally infected human host and accounts for most of the virus’ diverse and peculiar properties. We
have developed an agent-based computer model/simulation (PathSim, Pathogen Simulation) of this biological model.
The simulation is performed on a virtual grid that represents the anatomy of the tonsils of the nasopharyngeal cavity
(Waldeyer ring) and the peripheral circulation—the sites of EBV infection and persistence. The simulation is presented
via a user friendly visual interface and reproduces quantitative and qualitative aspects of acute and persistent EBV
infection. The simulation also had predictive power in validation experiments involving certain aspects of viral
infection dynamics. Moreover, it allows us to identify switch points in the infection process that direct the disease
course towards the end points of persistence, clearance, or death. Lastly, we were able to identify parameter sets that
reproduced aspects of EBV-associated diseases. These investigations indicate that such simulations, combined with
laboratory and clinical studies and animal models, will provide a powerful approach to investigating and controlling
EBV infection, including the design of targeted anti-viral therapies.
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Introduction
Computer simulation and mathematical modeling are
receiving increased attention as alternative approaches for
providing insight into biological and other complex systems
[1]. An important potential area of application is microbial
pathogenesis, particularly in cases of human diseases for
which applicable animal models are lacking. To date, most
simulations of viral pathogenesis have tended to focus on HIV
[2–7], and employ mathematical models based on differential
equations. None have addressed the issue of acute infection
by the pathogenic human herpes virus Epstein–Barr virus
(EBV) and its resolution into lifetime persistence. With the
ever-increasing power of computers to simulate larger and
more complex systems, the possibility arises of creating an in
silico virtual environment in which to study infection. We
have used EBV to investigate the utility of this approach. EBV
is a human pathogen, associated with neoplastic disease, that
is a paradigm for understanding persistent infection in vivo
and for which a readily applicable animal model is lacking
(reviewed in [8,9]). Equally important is that EBV infection
occurs in the lymphoid system, which makes it relatively
tractable for experimental analysis and has allowed the
construction of a biological model of viral persistence that
accounts for most of the unique and peculiar properties of
the virus [10,11]. We are therefore in a position to map this
biological model onto a computer simulation and then ask
how accurately it represents EBV infection (i.e., use our
knowledge of EBV to test the validity of the simulation) and
whether the matching of biological observation and simu-
lation output provides novel insights into the mechanism of
EBV infection. Speciﬁcally, we can ask if it is possible to
identify critical switch points in the course of the disease
where small changes in behavior have dramatic effects on the
outcome. Examples of this would be the switch from clinically
silent to clinically apparent infection and from benign
persistence to fatal infection (as occurs in fatal acute EBV
infection and the disease X-linked lymphoproliferative [12],
for example), or to clearance of the virus. Indeed, is clearance
ever possible, or do all infections lead inevitably to either
persistence or death? Such an analysis would be invaluable.
Not only would it provide insight into the host–virus balance
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that allows persistent infection, but it would also reveal the
feasibility and best approaches for developing therapeutic
interventions to diminish the clinical symptoms of acute
infection, prevent fatal infection, and/or clear the virus.
A diagrammatic version of the biological model is
presented in Figure 1. EBV enters through the mucosal
surface of the Waldeyer ring, which consists of the nasophar-
yngeal tonsil (adenoids), the paired tubal tonsils, the paired
palatine tonsils, and the lingual tonsil arranged in a circular
orientation around the walls of the throat. Here EBV infects
and is ampliﬁed in epithelium. It then infects naı¨ve B cells in
the underlying lymphoid tissue. The components of the ring
are all equally infected by the virus [13]. EBV uses a series of
distinct latent gene transcription programs, which mimic a
normal B cell response to antigen, to drive the differentiation
of the newly infected B cells. During this stage, the infected
cells are vulnerable to attack by cytotoxic T cells (CTLs) [14].
Eventually, the latently infected B cells enter the peripheral
circulation, the site of viral persistence, as resting memory
cells that express no viral proteins [15] and so are invisible to
the immune response. The latently infected memory cells
circulate between the periphery and the lymphoid tissue [13].
When they return to the Waldeyer ring they are occasionally
triggered to terminally differentiate into plasma cells. This is
the signal for the virus to begin replication [16], making the
cells vulnerable to CTL attack again [14]. Newly released
virions may infect new B cells or be shed into saliva to infect
new hosts, but are also the target of neutralizing antibody.
Primary EBV infection in adults and adolescents is usually
symptomatic and referred to as infectious mononucleosis
(AIM). It is associated with an initial acute phase in which a
large fraction (up to 50%) of circulating memory B cells may
be latently infected [17]. This induces the broad T lymphocyte
immune response characteristic of acute EBV infection.
Curiously, primary infection early in life is usually asympto-
matic. In immunocompetent hosts, infection resolves over a
period of months into a lifelong persistent phase in which ;1
in 105 B cells carry the virus [18]. Exactly how persistent
infection is sustained is unclear. For example, once persis-
tence is established, it is unknown if the pool of latently
infected memory B cells is self-perpetuating or if a low level
of new infection is necessary to maintain it. Indeed, we do not
know for sure that the pool of latently infected B cells in the
peripheral memory compartment is essential for lifetime
persistence. It is even unclear whether the virus actually
establishes a steady state during persistence or continues to
decay, albeit at an ever slower rate [17].
In the current study we describe the creation and testing of
a computer simulation (PathSim) that recapitulates essential
features of EBV infection. The simulation has predictive
power and has utility for experiment design and under-
Figure 1. Diagrammatic Representation of the Simulation and the Biological Model on which It Is Based
For a detailed description of the biological model, see Introduction and [9–11]. The simulation reflects the biological model with some simplifications
(for details see Methods). * denotes that amplification in the simulation is achieved by arbitrarily adding more Vir to the epithelial cell layer at each time
step.
doi:10.1371/journal.ppat.0030137.g001
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Author Summary
The possibility of using computer simulation and mathematical
modeling to gain insight into biological systems is receiving
increased attention. However, it is as yet unclear to what extent
these techniques will provide useful biological insights or even what
the best approach is. Epstein–Barr virus (EBV) provides a good
candidate to address these issues. It persistently infects most
humans and is associated with several important diseases, including
cancer. We have developed an agent-based computer model/
simulation (PathSim, Pathogen Simulation) of EBV infection. The
simulation is performed on a virtual grid that represents the
anatomy where EBV infects and persists. The simulation is presented
on a computer screen in a form that resembles a computer game.
This makes it readily accessible to investigators who are not well
versed in computer technology. The simulation allows us to identify
switch points in the infection process that direct the disease course
towards the end points of persistence, clearance, or death, and
identify conditions that reproduce aspects of EBV-associated
diseases. Such simulations, combined with laboratory and clinical
studies and animal models, provide a powerful approach to
investigating and controlling EBV infection, including the design
of targeted anti-viral therapies.
standing EBV infection. One practical limitation of available
simulation and modeling approaches has been their inacces-
sibility to the working biologist. This is often due to the use of
relatively unfamiliar computer interfaces and output formats.
To address these issues, we have presented the simulation via
a user-friendly visual interface on a standard computer
monitor. This allows the simulation to be launched and
output to be accessed and analyzed in a visual way that is
simple and easily comprehensible to the non-specialist.
Results
An Agent-Based Computer Simulation of EBV Infection:
Pathogen Simulation (PathSim)
The computer model (PathSim) is a representation of the
biological model described in the Introduction. A schematic
version of both is shown in Figure 1. To simulate EBV
infection, we created a virtual environment consisting of a
grid that describes a biologically meaningful topography, in
this case the Waldeyer ring (ﬁve tonsils and adenoids) and the
peripheral circulation, which are the main sites of EBV
infection and persistence. The tonsils and adenoids were
composed of solid hexagonal base units representing surface
epithelium, lymphoid tissue, and a single germinal center/
follicle (Figure 2A–2C; Video S1). Each hexagonal unit had
one high endothelial venule (HEV) entry point from the
peripheral blood and one exit point into the lymphatic
system (Figure 2A).
Discrete agents (cells or viruses) reside at the nodes (red
boxes) of the 3-D grid (white lines). There they can interact
with other agents and move to neighboring nodes. Agents are
assessed at regular, speciﬁed time intervals as they move and
interact upon the grid. Virtual cells were allowed to leave the
Waldeyer ring via draining lymphatics and return via the
peripheral blood and HEVs (Figure 2A and 2B; Video S1) as
in normal mucosal lymphoid tissue [19]. A brief summary list
of the agents employed in our simulation, and their proper-
ties and interactions, is given in Table 1. In this report we
refer to actual B cells as, for example, ‘‘B cells’’, ‘‘latently
infected B cells’’, or ‘‘lytically infected B cells’’, and their
virtual representations as ‘‘virtual B cells’’, ‘‘BLats’’, or ‘‘BLyts’’.
Similarly, we refer to actual virus as virions and their virtual
counterparts as virtual virus or Vir. A full description of the
simulation, including a complete list of agents, rules, the
default parameters that produce the output described below,
and a preliminary survey of the extended parameter space is
presented in M. Shapiro, K. Duca, E. Delgado-Eckert, V.
Hadinoto, A. Jarrah, et al. (2007) A virtual look at Epstein-
Barr virus infection: simulation mechanism (unpublished
data). Here, we will ﬁrst present a description of how the
virtual environment was visualized and then focus on a
comparison of simulation output with the known biological
behavior of the virus.
The Virtual Environment
Simulation runs were accessed through an information-
rich virtual environment (IRVE) (Figures 2 and 3; Videos S1
and S2), which was invoked through a Web interface. This
provided a visually familiar, straightforward context for
immediate comprehension of the spatial behavior of the
system [20]. It also allowed speciﬁcation of parameters, run
management, and ready access to data output and analysis.
Figure 3 demonstrates how the time course of infection
may be visualized. Usually the simulation was initialized by a
uniform distribution of Vir over the entire surface of the
Waldeyer ring, thereby seeding infection uniformly. How-
ever, in the simulation shown in Figure 3A, virtual EBV was
uniformly deposited only on the lingual tonsil. Figure 3B–3D
shows the gradual spread of virtual infection (intensity of red
color indicating the level of free Vir) to the adjacent tonsils. It
can be seen in this case that the infection spreads uniformly
to all the tonsils at once, implying that it was spreading via
BLats returning from the blood compartment and reactivating
to become BLyts, rather than spreading within the ring.
Examples of infectious spread between and within the tonsils
can also be seen in Video S2.
Simulation Output and Validation
Time course of infection. There were a number of
properties of the initial infection that were in agreement
when natural EBV infection was compared to the simulation.
Typical output from the simulation, employing the default
parameter set, is shown in Figure 4 along with relevant
biological data for comparison. Figure 4A shows the time
course for the number of BLats taken from multiple
simulation runs. Superimposed upon this are data from 15
individuals acutely infected with EBV (AIM patients). The
simulation showed several features with striking similarity to
natural infection (for a summary see Table 2). First, there was
a peak of infected cells that approached up to 50% of the
virtual B cells. This would seem unlikely; however, we have
previously documented that at the ﬁrst clinic visit by AIM
patients the number of infected memory B cells in the
periphery can indeed approach 50% [17]. Second, the peak of
virtual infected B cells (BLats) occurred at 33–38 d. This was in
good agreement with the published incubation period for
Table 1. A Summary of the Agents and Their Governing Rules
Used in This Simulation
Agents
B cells BNaive – represents uninfected naı¨ve B cells.
BLat – represents latently infected B cells, i.e., those which
are not producing Vir.
BLyt – represents lytically infected B cells.
T cells TNaive – represents unactivated T cells.
TLat – represents CTLs against latently infected B cells.
TLyt – represents CTLs against lytically infected B cells.
EB virions Vir – represents free virus.
Interactions
BNaives are either infected or die. They become latently
infected upon contact with Vir.
BLats are relatively long-lived. Some convert to BLyts
upon return from the blood compartment, replicate Vir and
die at burst.
Naı¨ve populations are replenished at variable rates,
depending on infection status, to maintain homeostasis.
Vir is cleared after an average number of time steps,
corresponding to antibody clearance.
TNaives convert to CTLs after encounters with their cognate
infected B cells and virus.
When virtual CTLs encounter their targets they kill them.
Virtual CTLs have finite life spans and are recycled as TNaives.
doi:10.1371/journal.ppat.0030137.t001
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Figure 2. Representative Fields from the Simulation’s Virtual Environment (IRVE)
For more details on (A–C), see Video S1, and for more on (D and E) see Video S2.
(A) The basic unit, used to construct the tonsil grid, consists of a solid hexagonal structure representing surface epithelium, lymphoid tissue, and a
single germinal center/follicle. The virtual grid along which the agents move is shown as white lines, and the nodes where agents reside and interact are
depicted as red boxes. Each hexagonal unit has one HEV entry point from the peripheral blood and one exit point into the lymphatic system.
(B) A view from the side of a single tonsil showing how the hexagonal base units are packed to create the entire grid of the tonsil lymphoepithelium.
(C) An overview of a single complete tubal tonsil showing part of its surface and part of its internal structure.
(D) Skull level view of the simulation showing the on screen control panel (bottom of figure) and an example of one form of graphic representation of
the global status of the infection (line graphs, left).
(E) A view at the level of the entire Waldeyer ring demonstrating different methods of quantitation. Graphics in the form of numbers (top left) or bar
graphs for a given time step and time line graphs (top right) are shown for various compartments of the simulation. The color signature for the ring is
red, which denotes free Vir. The color of the ring denotes the type and level of agent being shown. In this case, the intense red color indicates a high
level of free Vir throughout the ring (for an example of infection spreading throughout a single lymph node or the entire ring visualized by changing
color intensity, see Figure 3 and Video S2). Note also the draining lymphatics (white vessels) and peripheral circulation (red and blue vessels). These
images are screen shots taken on 7/30/2006.
doi:10.1371/journal.ppat.0030137.g002
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AIM of 35–50 d [21]. Third, there was a dramatic decline in
the levels of virtual infected cells that resolved into low-level
persistent infection that continued for the longest time
period we have examined (;3 y). We deﬁne persistence here
as the normal course of EBV infection, i.e., an acute infection
that clearly resolves into a long-term stable presence of much
lower levels of viral genomes both in latently infected cells
and as free virus. The overall decline in virtual infected cells
(and Vir production, see below) appeared to proceed more
and more slowly rather than come to a steady state, at least
for the time periods we have simulated. This behavior was
compatible with that seen in recent kinetic studies of acute
EBV infection [17].
The simulation was less precise in the absolute quantitation
of recovery. During the acute phase of AIM, the levels of
infected cells drop rapidly, with a half-life of approximately 7
d (V. Hadinoto, M. Shapiro, T. Greenough, J. Sullivan, K.
Luzuriaga, D. Thorley-Lawson (2007) On the dynamics of
acute EBV infection and the pathogenesis of infectious
mononucleosis (unpublished data)), to a level that is 103-fold
lower in 6 mo [17] and ultimately 104- to 105-fold lower
during persistent infection [13]. By comparison, virtual
infection resolved signiﬁcantly more slowly in the simulation,
with a half-life of ;21 d, and less well, with only ; a 20-fold
drop by 6 mo. This was followed by a marked oscillation with
a frequency of around 6 mo to 1 y and a drop of no more than
100-fold at the 1 y nadir. It is conceivable that oscillations
occur during natural infection with similar frequencies to
those seen in the simulation, but they would have to occur
with much smaller amplitudes since they have not been seen
in our studies to date (V. Hadinoto and D. Thorley-Lawson,
unpublished data).
An important caveat to these comparisons is that the
simulation presents the dynamics of infection in the
Waldeyer ring and the peripheral circulation, whereas the
dynamics of EBV infection in vivo has only been studied in
the peripheral blood and saliva. However, this is probably not
a major concern since we have shown previously that, at least
during persistent infection, the levels of infected B cells in the
peripheral blood and Waldeyer ring are comparable [13].
Thus, in terms of general quantitative and qualitative
features, this is the ﬁrst simulation to our knowledge to
reproduce both the acute and persistent phases of latent EBV
infection.
Viral replication and production. Another feature where
the simulation represented the known features of EBV
infection is Vir replication and production, which continued
at a low level throughout the persistent phase (Figure 4B and
4C). Furthermore, the fraction of virtual B cells replicating
Vir (;0.05%–0.1% in both acute and persistent phase) was
remarkably similar to what we have estimated for the tonsils
of persistently infected individuals (;0.05%–0.1% complete
the replicative cycle) [16]. One unusual feature of AIM was
that, while the levels of latently infected B cells were
decreasing exponentially for the ﬁrst 5–7 wk after the patient
had arrived in the clinic, the level of virus production by the
lymphoepithelium was already quite stable, declining very
little over the same time period ([22,23] and V. Hadinoto, M.
Shapiro, T. Greenough, J. Sullivan, K. Luzuriaga, et al. (2007)
On the dynamics of acute EBV infection and the pathogenesis
Figure 3. Progression of the Infection in a Typical Simulation as Visualized by the IRVE
This Figure is similar to Figure 2E except that different time points in the infection process are shown. Vir were seeded evenly over the lingual tonsil and
then allowed to spread to the rest of the ring. Note that in this case as time progresses (A–D) the infection spreads evenly to all of the other tonsils and
adenoids as indicated by a gradual uniform increase of color intensity. These images are screen shots taken on 3/7/2007.
doi:10.1371/journal.ppat.0030137.g003
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of infectious mononucleosis (unpublished data)). This feature
was also observed in the simulation if we assume that
individuals enter the clinic at or soon after peak infection
of B cells. Figure 4C compares the overall dynamics of BLat
and virtual virus (Vir) production during a simulated
infection. By day 50, Vir production had already declined
close to persistent levels, whereas the number of BLat was still
falling exponentially and continued to do so for approx-
imately another 50 d. The insert in Figure 4C shows
comparative representative data from a single AIM patient.
In this case, again, virion shedding remained relatively stable
for at least 60 d (Figure 4C and not shown) after the ﬁrst
clinic visit, whereas the levels of latently infected memory B
cells fell rapidly. As before, the levels of latently infected
memory B cells fell much more rapidly in actual infection
compared to the simulation.
The simulation was also accurate in modeling certain
detailed aspects of virus production. Thus, during a real
persistent infection, virus production, as judged by shedding
into saliva, was highly variable (V. Hadinoto and D. Thorley-
Lawson, unpublished data), with 3 logs difference over the
course of a year (Figure 4D, range from 7.33 102 to 1.83 107
virions/ml of saliva), whereas we have shown previously that
the level of latently infected B cells in the blood is relatively
stable for years [18]. When we looked at similarly spaced time
points from a simulation run, we found the same degree of
variation in Vir production (Figure 4D, range 13 103 to 1.33
103) while the level of BLats over a similar period was again
quite stable (e.g., compare BLat and Vir production in Figure
4C).
There is also a caveat to these comparisons. The simulation
reports the total number of Vir present, whereas in a real
infection, we can only measure viral shedding in the saliva.
We make the assumption that these two events are at least
proportionally related to each other. Given this caveat, we
can conclude that the simulation also reproduces the overall
Figure 4. Output of the Simulation Employing the Default Parameter Set Matched to Biological Data
(A) Simulation output of the total number of latently infected virtual B cells (BLat) over time in a series of superimposed simulation runs (colored lines)
versus the number of actual latently infected memory B cells in the peripheral blood of 15 acutely infected individuals over time (colored circles). The
first patient time point is assumed to be at 50 dþ/ 10 d (see text for explanation). The simulation runs all use the default parameter set. Stochasticity
(i.e., random variations) in the runs are a consequence of the fact that every interaction and motion of agents is governed by a probability and a
variability function. So, for example, the initial infectious dose will vary from node to node in the epithelium and will have a certain average. This
average we refer to as the initial infectious dose. For a detailed discussion of all the rules governing interactions and motion, see M. Shapiro, K. Duca, E.
Delgado-Eckert, V. Hadinoto, A. Jarrah, et al. (2007) A virtual look at Epstein-Barr virus infection: simulation mechanism (unpublished data).
(B) Simulation output of the total number of latently infected virtual B cells (BLat) and virtual B cells replicating virtual virus (BLyt) over time for a single
simulation run.
(C) Simulation output of the level of latently infected virtual B cells (BLat) and free virtual virus (Vir) over time for a single simulation run. The insert shows
a time course for a typical acutely infected patient for the first 25 d after entering the clinic showing the level of latently infected memory B cells in the
peripheral blood and free virions shed into the saliva.
(D) The level of virtual free virus (Vir) over 1 y in the simulation (blue line). The level was assessed every 25 d, once the simulation had entered into the
persistent phase defined as a stable level of latently infected virtual B cells (BLat) For comparison, the level of shed virus (Virions) in the saliva of a
persistently infected individual, sampled on average approximately every 30 d, is shown (red line). The x-axis denotes the number of days over which
sampling was performed and does not relate to the time from initial infection
N.B. Note this figure only allows analysis of overall dynamics, not absolute numbers, since all comparisons between simulation and in vivo data are
relative.
doi:10.1371/journal.ppat.0030137.g004
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dynamics of viral replication during infection. We can extend
this claim to conclude that these studies provide the ﬁrst
evidence to our knowledge that the simulation has predictive
power, because the observations of stochasticity in virus
production and of the discrepancy in the time of stabilization
for the levels of virus shedding and B latent were seen in the
simulation before being tested and observed experimentally.
The peripheral memory compartment is required for long-
term persistence. One advantage of a simulation strategy is
that it allows us to track the consequences of altering
conditions and parameters that would not necessarily be
feasible in a human. A central, but unproven, tenet of the
EBV model is that the pool of immunologically invisible,
latently infected memory B cells in the peripheral circulation
is the site of and essential for lifetime persistence. To address
this question in silico, we ran the simulation while maintaining
the default parameter set, but prevented access of infected
BLats to the peripheral circulation. In this case, we observed a
characteristic series of spikes in BLats that was lost after
approximately 30–40 d. (Figure 5A). The explanation for
these spikes is that in a normal run, BLats spend time in the
circulation, and the time they spend there does not advance
them towards the lytic state. By denying them access to the
blood, both the mean time to burst and the standard
deviation of this statistic decrease. This causes the virtual
viral bursts and infection of new virtual B cells to arrive as
narrow spikes, one spike per generation of infected virtual
cells.
Since the maintenance of persistent infection appeared
dependent on the availability of a peripheral compartment,
we wondered how robust this dependence was. To address
this we attempted to compensate for lack of access to the
circulation by raising either the initial infectious dose of Vir
or the burst size or by weakening the immune system (Figure
5B–5D). Raising the initial infectious dose (Figure 5B) or
burst size (Figure 5C) had little impact on the overall
dynamics, with both still leading to clearance, albeit increased
burst size did delay this by about 30 d. It is conceivable that by
increasing burst size even further a virtual infection could be
generated where virtual virus was still present at the end of
the simulation run; however, it would require highly
unphysiological levels of bursting and generate an output
consisting of wild oscillations with a periodicity of about 10 d,
nothing like real EBV persistence. One counterintuitive
observation was that increasing the initial infectious dose
actually led to a reduction in the peak of acute infection. The
explanation for this is that the higher initial levels of Vir
stimulate a more aggressive immune response. A similar
phenomenon is seen in the presence of a peripheral
compartment (see below).
Reduction of CTL function by 75% (Figure 5D, blue line)
or more resulted in an acute accumulation of BLat, which
rapidly and irreversibly overwhelms the B cell compartment.
By carefully titrating back the virtual immunosuppression to
50% (Figure 5D, brown line), it was possible to attain an
infection that had not cleared nor overwhelmed the B cell
compartment by the end of the run (880 d). In this case, we
see large oscillations of the BLat population with a very slow
trend upward, suggesting that the B cell compartment will
eventually be overwhelmed. It was interesting to note that the
periodicity of these large swings (75–100 d) is similar to that
seen for chronic fatigue syndrome [24], which had originally
been linked to EBV, but for which causation remains unclear.
In this syndrome, patients develop symptoms of an acute
virus infection every few months. Our simulation output
raises the possibility that chronic fatigue syndrome could be
caused by a virus or viruses like EBV that are denied full
access to their site of persistence, where they are no longer
under immunosurveillance, in the presence of mild immu-
nosuppression such as stress, which is a known co-factor in
chronic fatigue syndrome.
In summary, for the range of parameters we have tested, it
was not possible to obtain a virtual persistent infection
characteristic of EBV in the absence of a peripheral B cell
pool. This suggests that access of BLats to the peripheral pool,
the equivalent to the circulating memory B latent, is required
for persistent infection and is consistent with the clinical
observations that the B cell compartment is essential for
persistence [25,26].
Effect of initial infectious dose on long-term persistence.
We wanted to test how robust persistence was in the presence
of the blood compartment, i.e., had we fortuitously picked
just the right conditions for persistence. We found that it was
robust over a wide range of parameters. Two examples are
given in Figure 6A and 6B. First, we tested the outcome of
varying the initial infectious dose of Vir from 103–106 (default
value ’ 53 104). For comparative purposes we note that we
detect ;104–107 viral genomes in thorough mouth rinses
from healthy carriers of EBV (V. Hadinoto and D. Thorley-
Lawson, unpublished data). Thus, the range we have tested
would be consistent with 10% of actual virions in the saliva
being infectious, which may be an overestimate. What we
observed (Figure 6A) was that the level of input Vir affected
the level of acute infection but had no impact on the level of
persistent infection. An interesting feature was that as the
initial infectious dose increased, the severity of acute
infection tended to decrease as measured by the level of
BLat. This happens because the higher dose provokes a more
aggressive immune response that controls the infection
process more efﬁciently. This observation raises the interest-
ing possibility that a low dose of infectious virus may actually
be more likely to contribute to development of AIM than a
high dose. There are many possible biological explanations
for how this variation in infectious dose could actually arise.
For example, the permeability of the epithelial layer to the
virus may be greater in children than adults, allowing a much
smaller fraction of the infectious dose access to the lymphoid
compartment in adults.
Although it is generally believed that EBV persists in the
mature B lymphoid compartment, there is a growing
consensus that it also infects epithelial cells in the nasophar-
yngeal region [27–29]. The role of this type of infection is
unclear but likely to involve ampliﬁcation of the virus since
EBV infection of epithelial cells seems to give rise to high
level replication rather than long-term latency [30]. A
contribution of the epithelial compartment to Vir produc-
tion was not included in the initial simulation; however, a
revised simulation with epithelial ampliﬁcation of Vir was
constructed by introducing additional Vir at the epithelial
surface at each time step (* in Figure 1). Effectively, this was
also a way to increase input Vir. Again, it had virtually no
impact on the long-term levels of BLat over a range of 4 logs in
ampliﬁcation (Figure 6B).
In summary, these results predict that the level of B cell
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infection during persistence will be independent of the
starting dose of input virus and that epithelial ampliﬁcation
is not required to establish or maintain persistent infection.
The fraction of BLats reactivating upon return to the
Waldeyer ring represents a critical switch point. One critical
feature to which the establishment of virtual persistence was
very sensitive was the rate at which BLats become BLyts and
begin producing new progeny Vir upon return from the
blood to the Waldeyer ring. As this rate was increased, there
was a sharp switch point where the virtual infection no longer
declined into persistence but overwhelmed the virtual B cell
compartment with infected virtual B cells, leading to what we
term virtual death within 2 wk (Figure 6C). This type of
catastrophic acute infection leading to rapid death is typical
of the disease course of the fatal acute EBV infection X-linked
lymphoproliferative disease [12] and provides an example of
how a relatively small change in a biological parameter at a
critical time in the infection can dramatically change the
outcome. It was also striking that the maximal fraction of
returning BLats that could reactivate to BLyts and still allow the
establishment of persistence (;0.1%–0.2%) was very close to,
but slightly higher than, the fraction we have actually
measured in the tonsils of healthy carriers (;0.05%–0.1%
complete the replicative cycle) [16]. This raises the possibility
that host and virus have co-evolved to allow the maximal
amount of viral reactivation possible, presumably to max-
imize the chance of virus spread to new hosts, without putting
the host at risk for fatal acute infection that would result in
the death of both host and virus.
Discussion
In this paper we present a comprehensive model of EBV
infection that effectively simulates the overall dynamics of
acute and persistent infection. The fact that this simulation
can be tuned to produce the course of EBV infection suggests
that it models the basic processes of this disease. To achieve
this, we have created a readily accessible, virtual environment
that appears to capture most of the salient features of the
lymphoid system necessary to model EBV infection. Achiev-
ing infection dynamics that reﬂect an acute infection
followed by recovery to long-term low-level persistent
infection seems to require access of the virus to a blood
compartment where it is shielded from immunosurveillance.
Because we cannot perform a comprehensive parameter
search (due to the very large parameter space involved), we
cannot unequivocally state that the blood compartment is
essential. What is clear though, is that persistence is a very
robust feature in the presence of a blood compartment, and
that we could not achieve an infection process that even
remotely resembles typical persistent EBV infection in its
absence.
The areas in which the simulation most closely follows
known biology are summarized in Table 2 and include the
peak time of infection, 33–38 d, compared to the incubation
time for AIM of 35–50 d [21]. This predicts that patients
become sick and enter the clinic at or shortly after peak
infection in the peripheral blood, a prediction conﬁrmed by
our patient studies, where the numbers of infected B cells in
the periphery always decline after the ﬁrst visit [17].
An important feature of a simulation is its predictive
power. Our analysis predicted that access to the peripheral
memory compartment is essential for long-term persistence.
This is consistent with recent studies on patients with hyper-
IgM syndrome [31]. Although these individuals lack classical
memory cells, they can be infected by EBV; however, they
cannot sustain persistent infection and the virus becomes
undetectable. Unfortunately, those studies did not include a
sufﬁciently detailed time course to see if time to virus loss
coincided with the simulation prediction of 1–2 mo.
Another area where the simulation demonstrated its
predictive power was in the dynamics of viral replication.
In the simulation it was unexpectedly observed that the level
of Vir production plateaued long before BLats, predicting that
the levels of virus shedding, unlike latently infected cells, will
have leveled off by the time AIM patients arrive in the clinic.
This prediction, which contradicted the common wisdom
that virus shedding should be high and decline rapidly in AIM
patients, was subsequently conﬁrmed experimentally (V.
Hadinoto, M. Shapiro, T. Greenough, J. Sullivan, K. Luzur-
iaga, D. Thorley-Lawson (2007) On the dynamics of acute EBV
infection and the pathogenesis of infectious mononucleosis
(unpublished data) and see also [22,23]). The simulation also
quite accurately reproduces the relatively large variation in
Table 2. Validation of Simulation Output
Parameter Simulation In Vivo
Quantitative
Persistence .2 years Lifetime
Peak Infection ;35 days Incubation period 35–50 days
% infected cells at peak ;50% Up to 50%
Relative levels of B lytic to B latent ; 0.5% 0.1%–0.5%
Changes in virus shedding Minor after 35–40 days Minor after first clinic visit (35–50 days)
Decay of B latent Exponential, half-life 21 days Exponential, half-life 7days
Low level persistence of B latent 100-fold lower than peak value 103–104 fold lower than peak value
Biological
Memory compartment Required for persistence Required for persistence
Epithelial amplification Not required for persistence Unable to sustain persistence
Persistence Slow decay, no equilibrium, oscillation. Slow decay, no equilibrium, no oscillation.
Input infectious dose No effect on long term persistence Confirmed in MHV68 [35].
doi:10.1371/journal.ppat.0030137.t002
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virus production over time, compared to the stability of B
latent. This difference is likely a consequence of stochasticity
(random variation) having a relatively larger impact on virus
production. This is because the number of B cells replicating
the virus at any given time is very small, both in reality and
the simulation, compared to the number of infected B cells,
but the number of virions they release when they do burst is
very large. This difference may reﬂect on the biological
requirements for persistence of the virus since a transient loss
in virus production due to stochasticity can readily be
overcome through recruitment from the pool of B latents.
However, a transient loss of B latents would mean clearance
of the virus. Hence, close regulation of B latent but not virion
levels is necessary to ensure persistent infection.
Although there is now a growing consensus that EBV
infects normal epithelial cells in vivo [27–29], the biological
signiﬁcance of this infection remains unclear. The available
evidence suggests that epithelial cell infection may not be
required for long-term persistence [25,26], and this is also
seen in the simulation. The alternate proposal is that
epithelial infection might play an important role in amplify-
ing the virus, during ingress and/or egress, as an intermediary
step between B cells and saliva. This is based on the
observation that the virus can replicate aggressively in
primary epithelial cells in vivo [30]. In the simulation,
epithelial ampliﬁcation had no signiﬁcant effect on the
ability of Vir to establish persistence. This predicts that
epithelial ampliﬁcation does not play a critical role in entry
of the virus, but leaves open the possibility that it may be
important for increasing the infectious dose present in saliva
for more efﬁcient infection of new hosts.
The simulation is less accurate in the precise quantitation
Figure 5. Access to the Peripheral Circulation Is Required for Viral Persistence in the Simulation
(A) The virtual virus does not persist when latently infected virtual B cells (BLat) are denied access to the peripheral circulation. The graph shows the level
of BLats over time for a simulation run with the default parameter set allowing (red line) or denying (brown line) access of the BLats to the peripheral
circulation Note that only the first 60 d of virtual infection are shown. A characteristic series of spikes in BLats is observed that was lost after approximately
30–40 d. These spikes arise because normally BLats spend time in the circulation, and the time they spend there does not advance them towards the lytic
state. By denying them access to the blood, both the mean time to burst and the standard deviation of this statistic decrease. This causes the virtual viral
bursts and infection of new virtual B cells to arrive synchronously as narrow spikes, one spike per generation of infected virtual cells.
(B) Increasing the initial infectious dose does not allow persistence in the absence of a peripheral blood compartment. The simulation was run without a
peripheral blood compartment as described in (A), except the initial infectious dose was increased in increments as shown. The initial infectious dose is
the average number of Vir deposited at each mesh point (node) on the surface of the virtual lymphoepithelium. To obtain the total infectious dose, this
value is multiplied by the number of surface nodes (16,205). The figure shows runs with infectious dose of 7/mesh point (pink line) and 70/mesh point
(green line). The default value for initial infectious dose is 0.7/mesh point.
(C) Increasing the Vir burst size does not allow persistence in the absence of a peripheral blood compartment. The simulation was run without a peripheral
blood compartment as described in (A), except the number of Virs released when a BLyt bursts was doubled (default average burst size¼ 800 Virs).
(D) Decreasing the efficiency of the immune response does not allow persistence in the absence of a peripheral blood compartment. The simulation
was run without a peripheral blood compartment as described in (A), except the efficiency with which CTLs are activated and kill their targets was
reduced incrementally. With this approach it was possible to find a level of virtual immunosuppression (50% brown line) that produced an infection that
lasted for the length of the simulation (880 virtual days). However, this looks nothing like EBV persistence in a real infection. Rather, the virtual infection
involves wild oscillations in the number of latently infected virtual B cells (BLat) and it appears that the average level is trending upwards to overwhelm
the B cell compartment, a condition we refer to as virtual death. Small incremental increases above 50% immunosuppression (e.g., 75% blue line)
resulted in the B cell compartment being rapidly overwhelmed with latently infected virtual B cells (BLat). Small incremental decreases below 50%
immunosuppression resulted in clearance of Vir similar to that seen in Figure 5A.
doi:10.1371/journal.ppat.0030137.g005
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of the dynamics. Virtual acute infection resolves signiﬁcantly
more slowly and persistence is at a higher level than in a real
infection. In addition, virtual persistent infection demon-
strates clear evidence of oscillations in the levels of infected
cells that have not been detected in a real infection. The most
likely explanation for these discrepancies is that we have not
yet implemented T cell memory. Thus, as the levels of virtual
infected cells drops, the immune response weakens, allowing
Vir to rebound while a new supply of virtual CTLs is
generated. Immunological memory would allow a more
sustained T cell response that would produce a more rapid
decline of infected cells, lower levels of sustained persistence,
and tend to ﬂatten out oscillatory behavior, thus making the
simulation more quantitatively accurate. This is one of the
features that will be incorporated into the next version of our
simulation. It remains to be determined what additional
features need to be implemented to sharpen the model and
also whether and to what extent the level of representation
we have chosen is necessary for faithful representation of
EBV infection. Our simulation of the Waldeyer ring and the
peripheral circulation was constructed with the intent of
modeling EBV infection. Conversely, our analysis can be
thought of as the use of EBV to validate the accuracy of our
Waldeyer ring/peripheral circulation simulation and to
evaluate whether it can be applied to other pathogens. Of
particular interest is the mouse gamma herpesvirus MHV68
[32,33]. The applicability of MHV68 as a model for EBV is
controversial. Although it also persists in memory B cells [34],
it appears to lack the sophisticated and complicated latency
states that EBV uses to access this compartment. However,
one of the simpliﬁcations in our simulation is that the details
of these different latency states and their transitions are all
encompassed within a single concept, the BLat. We have also
assumed a time line whereby a newly infected BLat becomes
activated and CTL sensitive, migrates to the follicle, and exits
into the circulation, where it is no longer seen by our virtual
CTLs. In essence, we have generalized the process by which
the virus proceeds from free virion to the site of persistence
in such a way that it may be applicable to both EBV and
MHV68. Thus, we might expect that the overall dynamics of
infection may be similar even though detailed biology may
vary. As a ﬁrst step to test if this concept had value, we
performed an analysis based on studies with MHV68 where it
was observed that the levels of infected B cells at persistence
were unaffected by the absolute amount of input virus at the
time of infection [35]. When this parameter was varied in the
simulation, we saw the same outcome. This preliminary
attempt raises the possibility that the mouse virus may be
useful for examining quantitative aspects of EBV infection
dynamics.
The last area we wished to investigate was whether we could
identify biologically meaningful ‘‘switch’’ points, i.e., places in
time and space where relatively small changes in critical
parameters dramatically affect outcome, for example, switch-
ing from persistence to clearance to death. We have observed
one such switch point—reactivation of BLats upon return to
the Waldeyer ring—that rapidly switches the infection
process from persistence to death. How this might relate to
fatal EBV infection, X-linked lymphoproliferative disease, is
uncertain. However, viral production is a function both of
how many B cells initiate reactivation and how efﬁciently
they complete the process. We believe that most such cells are
killed by the immune response before they release virus [16],
so defects in the immune response could allow more cells to
complete the viral replication process and give the same fatal
outcome.
The ability to ﬁnd such conditions for switch points could
be very useful in the long term for identifying places in the
infection process where the virus might be optimally
vulnerable to drug intervention. The easiest place to target
EBV is during viral replication; however, it is currently
unclear whether viral replication and infection are required
for persistence. It may be that simply turning off viral
replication after persistence is established fails to eliminate
Figure 6. Comparing Simulation Output, Employing the Default Parameter Set, to What Is Known or Expected from a Real Infection
(A) Varying the initial infectious dose of Vir has no effect on persistent levels of latently infected virtual B cells (BLat). The initial infectious dose is the
average number of Vir deposited at each mesh point (node) on the surface of the virtual lymphoepithelium. The simulation was run as described in
Figure 4A, except the initial infectious dose of Vir was varied from 0.1 to 10 as shown (the default level is 0.7). Since there are 16,205 surface mesh
points, this translates into a total infectious dose ranging from 1.63 103 to 1.63 105.
(B) Epithelial cell amplification has no effect on persistent levels of latently infected virtual B cells (BLat). Epithelial cell amplification of Vir was simulated
by adding an additional amount of Vir at each time step. The virtual amplification achieved varied from none to 23 104.
(C) Persistence is highly sensitive to the rate of Vir reactivation. The simulation was run as described in Figure 4A, except the percentage of latently
infected virtual B cells (BLat) that initiate Vir replication upon return to the Waldeyer ring was varied as shown (the default percentage is 0.05% based on
data from [16]).
doi:10.1371/journal.ppat.0030137.g006
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the virus because the absence of new cells entering the pool
through infection is counterbalanced by the failure of
infected cells to disappear through reactivation of the virus.
If, however, a drug allowed abortive reactivation, then cells
would die without producing infectious virus and new
infection would be prevented. This models the situation that
would arise with a highly effective drug or viral mutant that
blocked a critical stage in virion production (e.g., viral DNA
synthesis or packaging), so that reactivation caused cell death
without release of infectious virus. A similar effect could be
expected with a drug or vaccine that effectively blocked all
new infection. This is another case in which studies with the
mouse virus, where non-replicative mutants can be produced
and tested, may be informative as to whether and to what
extent infection is required to sustain the pool of latently
infected B cells and persistence. The simulation could then be
used to predict how effective an anti-viral that blocked
replication, or a vaccine that induced neutralizing antibodies,
would need to be at reducing new infection in order to cause
EBV to be lost from the memory pool (for a more detailed
discussion of this issue see M. Shapiro, K. Duca, E. Delgado-
Eckert, V. Hadinoto, A. Jarrah, et al. (2007) A virtual look at
Epstein-Barr virus infection: simulation mechanism (unpub-
lished data)).
Most modeling of virus infection to date has tended to
focus on HIV and use differential equations [2–7]. One such
study involved EBV infection [36], but to our knowledge none
outside of our group has addressed the issue studied here of
acute EBV infection and how it resolves into lifetime
persistence. In preliminary studies of our own, modeling
EBV infection with differential equations that incorporate
features common to the HIV models, with parameters
physiologically reasonable for EBV did not produce credible
dynamics of infection (K. Duca, unpublished observations).
Although we do not exclude the possibility that such models
may be useful for simulating EBV, we took an agent-based
approach because it is intuitively more attractive to biolo-
gists. Such models are increasingly being recognized as an
effective alternative way to simulate biological processes [37–
39] and have several advantages. The main advantage is that
the ‘‘agent’’ paradigm complies by deﬁnition with the discrete
and ﬁnite character of biological structures and entities such
as organs, cells, and pathogens. This makes it more accurate,
from the point of view of scientiﬁc modeling. It is also less
abstract since the simulated objects, processes, and inter-
actions usually have a straightforward biological interpreta-
tion and the spatial structure of the anatomy can be modeled
meticulously. The stochasticity inherent to chemical and
biological processes can be incorporated in a natural way.
Lastly, it is generally much easier to incorporate qualitative
or semi-quantiative information into rule sets for discrete
models than it is for such data to be converted to accurate
rate equations. The major drawback to agent-based models is
that there is currently no mathematical theory that allows for
rigorous analysis of their dynamics. Currently, one simply
runs such simulations many times and performs statistical
analyses to assess their likely behaviors. Developing such a
mathematical theory remains an important goal in the ﬁeld.
In summary, we have described a new computer simulation
of EBV infection that captures many of the salient features of
acute and persistent infection. We believe that this approach,
combined with mouse modeling (MHV68) and EBV studies in
patients and healthy carriers, will allow us to develop a more
profound understanding of the mechanism of viral persis-
tence and how such infections might be treated and
ultimately cleared.
Methods
Biological data. Details of the AIM patient populations tested have
been published previously [17]. Adolescents (ages 17–24) presenting
to the clinic at the University of Massachusetts at Amherst Student
Health Service (Amherst, Massachusetts, United States) with clinical
symptoms consistent with acute infectious mononucleosis were
recruited for this study. Following informed consent, blood and
saliva samples were collected at presentation and periodically
thereafter. Diagnosis at the time of presentation to the clinic
required a positive monospot test and the presence of atypical
lymphocytes [21]. Conﬁrmation of primary Epstein–Barr infection
required the detection of IgM antibodies to the EBV viral capsid
antigen in patient sera [40]. These studies were approved by the
Human Studies Committee at the University of Massachusetts
Medical School (Worcester, Massachusetts, United States) and by
the Tufts New England Medical Center and Tufts University Health
Sciences Institutional Review Board. All blood samples were diluted
1:1 in 1x PBS.
The technique for estimating the absolute number of latently
infected B cells in the peripheral blood of patients and healthy
carriers of the virus is a real-time PCR–based variation of our
previously published technique [17], the details of which will be
published elsewhere (V. Hadinoto, M. Shapiro, T. Greenough, J.
Sullivan, K. Luzuriaga, et al. (2007) On the dynamics of acute EBV
infection and the origins of infectious mononucleosis (unpublished
data)). To measure the absolute levels of virus shedding in saliva,
individuals were asked to rinse and gargle for a few minutes with 5 ml
of water and the resultant wash processed for EBV-speciﬁc DNA PCR
using the same real-time–based PCR technique. We have performed
extensive studies to standardize this procedure that will be detailed
elsewhere (V. Hadinoto, M. Shapiro, T. Greenough, J. Sullivan, K.
Luzuriaga, et al. (2007) On the dynamics of acute EBV infection and
the origins of infectious mononucleosis (unpublished data)).
The simulation. In the simulation, B cells are either uninfected
(BNaı¨ve), latently infected (BLat), or replicating virtual virus (BLyt); we
do not distinguish blast and memory B cells. In the biological model,
newly infected B cells in the lymphoepithelium of the Waldeyer ring
pass through different latency states, which are vulnerable to attack
by cytotoxic T cells (CTL latent). Subsequently, they become memory
B cells that enter the peripheral circulation and become invisible to
the immune response by turning off viral protein expression. In the
simulation, all these latency states are captured in the form of a single
entity, the BLat. In addition, the blood circulation and lymphatic
system are both represented as abstract entities that only allow for
transport of BNaı¨ves and BLats around the body. Virtual T cells are
restricted to the Waldeyer ring. This simpliﬁcation is based on the
assumption that, in the biological model, EBV-infected cells entering
the peripheral circulation are normal and invisible to CTLs, because
the virus is inactive, and therefore the peripheral circulation simply
acts as an independent pool of and a conduit for B latent.
Operationally, therefore, BLats escape TLats in the simulation simply
by entering the peripheral circulation. Consequently, unlike the
biological model, BLats are vulnerable to TLats whenever they reenter
the lymph node.
Each agent (e.g., Vir or a BNaı¨ve) has a deﬁned life span, instructions
for movement, and functions that depend on which other agents they
encounter (for example, if a Vir encounters a BNaı¨ve, it infects it with
some deﬁned probability). The agents, rules, and parameters used are
based on known biology wherever possible with simpliﬁcations (see
above) where deemed appropriate. A brief description and discussion
of the agents and their rules is given in Table 1. A detailed listing is
provided in M. Shapiro, K. Duca, E. Delgado-Eckert, V. Hadinoto, A.
Jarrah, et al. (2007) A virtual look at Epstein-Barr virus infection:
simulation mechanism (unpublished data). At each time point (6 min
of real time), every agent is evaluated and appropriate actions are
initiated.
The IRVE. The simulation is invoked through a Web interface
(IRVE; see movies linked to Figure 2, and [20]) that allows a
straightforward visual, familiar, and scalable context for access to
parameter speciﬁcation, run management, data output, and analysis.
This has the additional advantage that it readily allows comprehen-
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sion of the spatial behavior of the system (e.g., ‘‘how does the
infection spread?’’). The simulation may also be invoked from the
command line. Through the Web, users can process simulation data
for output and analysis by a number of common applications such as
Microsoft’s Excel, University of Maryland’s TimeSearcher [41], and
MatLab.
We have developed display components that encapsulate multiple-
view capabilities and improved multi-scale interface mappings. The
IRVE is realized in the international standard VRML97 language. The
simulation can be rerun and reanalyzed using a normal VCR-type
control tool, which allows the operator, for example, to fast forward,
pause, rewind, or drag to a different time point, and to play back runs
or analyze simulation output dynamically. In the IRVE, any spatial
object (including the global system) can be annotated with absolute
population numbers (as a time plot and/or numeric table) or
proportional population numbers (as a bar graph) for any or all of
the agents. Spatial objects themselves can be animated by heat-map
color scales. The intensity of the color associated with each agent is a
measure of the absolute level of the agent; so, for example, as the level
of free Vir increases, so will the level of intensity of the associated
color (in this case red) both within the single units and in the entire
organ.
In our simulation we manage multiple views of the dynamic
population values through a higher order annotation called a
PopView (population view). A PopView is an interactive annotation
that provides three complementary representations of the agent
population. The representations can be switched through in series by
simple selection. The default view is a color-coded bar graph where
users can get a quick, qualitative understanding of the agent
populations in a certain location at that time step. The second is a
ﬁeld-value pair text panel, which provides numeric readouts of
population levels at that time step. The third is a line graph where the
population values for that region are plotted over time.
Because of the large amount of time points and the large number
of grid locations, the IRVE manages an integrated information
environment across two orders of magnitude: ‘‘Macro’’ and ‘‘Micro’’
scales. Through the standard VRML application the user has a
number of options including free-navigational modes such as: ﬂy,
pan, turn, and examine. This allows users to explore the system,
zooming in and out of anatomical structures as desired. In addition,
the resulting visualization space is navigable by predeﬁned view-
points, which can be visited sequentially or randomly through menu
activation. This guarantees that all content can be accessible and
users can recover from any disorientation. The Visualizer manages
Macro and Micro scale result visualizations using proximity-based
ﬁltering and scripting of scene logic. As users approach a given
anatomical structure, the micro-scale meshes and results are loaded
and synchronized to the time on the users’ VCR controller.
Supporting Information
Video S1. The Fine Structure of the Simulation Grid Visualized
through the IRVE
In this video, a single tonsil, the right tubal, is initially viewed as a
collection of 144 of the hex units that are the basic component of the
simulation. The video pans and then zooms in to reveal the ﬁne
structure of each unit and the grid that composes it. The tissue
structures represented are shown in detail, including the single HEV
entry point from the peripheral circulation and the exit point to the
lymphatics. The video then zooms into the tonsil, revealing the
network along which the agents move (represented as white lines) and
the nodes where the agents reside and interact (red boxes).
Found at doi:10.1371/journal.ppat.0030137.sv001 (68.4 MB AVI).
Video S2. An Overview of the Simulation Visualized through the
IRVE
This video demonstrates the ﬂexibility available through the motion
tools to enter and move around the simulation and through the
graphics tools to access data. It begins with a whole body view with
the general control panel for running the simulation shown at the
bottom. The global levels of different agents are represented as color-
coded bar graphs. Red represents Vir, green uninfected naı¨ve B cells,
yellow BLat, white BLyt dark blue naı¨ve T cells, purple CTLLat, and
light blue CTLLyt. The controls are similar to a typical VCR control. It
allows the operator to fast forward, pause, rewind, or drag the blue
cursor to a different time point and the capability to play back runs
or analyze simulation output dynamically. The pointer then reveals
how with a simple click the global statistics can be switched from a
bar graph to numeric values to a time-dependent line graph. The
pointer is then used to show how the data graphs can be easily
rotated, magniﬁed, or dragged to a different location for convenient
viewing. The pointer is then used to drag the blue cursor on the
control panel and it can be seen that an equivalent cursor moves
across the line graph, allowing precise selection of the time step to be
viewed.
The view then moves to the next layer, the Waldeyer ring in the skull,
whilst demonstrating that graphic data can be obtained at any level of
the simulation. The tonsils, adenoids, and connecting tissue are seen
along with the access for the peripheral circulation (red and blue
vessels) and lymphatics (white vessels). The image demonstrates the
versatility of the simulation, allowing motion into and through the
Waldeyer ring whilst at any time selecting data presentations for each
compartment or for the global values. The color of the ring indicates
the agent being monitored and its intensity the amount. Thus, when
the selection switches to red, we observe Vir levels just after peak
infection. The blue cursor is dragged back in time to the beginning
and the increase and subsequent decrease in Vir are visualized by the
change in color intensity. Meanwhile, the qualitative information
provided by the color intensity can be precisely quantitated at any
time by selecting the appropriate data box. The selected color then
changes to white, allowing the level of BLyt to be monitored as the
infection spreads and then run back simply by dragging the cursor.
The selected color then changes to purple allowing the spread of
CTLLyt to be monitored as the cursor is dragged.
The video then zooms into a single tonsil, the right palatine, while
continuing to demonstrate that local and global data can always be
accessed. The initial shot shows the saturation of the tonsil with Vir.
The cursor is then dragged back and forth to the beginning,
demonstrating the changes in level of Vir over time. The video then
pans sideways to reveal that the level of infection within individual
hex units can be visually appreciated both by the intensity of the
color and the height of a bar for each unit. At one point it can readily
be appreciated that the spread of free Vir is occurring from the right
to the left of this particular view. The cursor is again dragged back
and forth to show how the infection spreads till peak value at the
height of the acute infection and then slowly recedes as the infection
moves into long-term persistence. The same sequence is then
analyzed from the standpoint of CTLLyt (in purple). The video then
momentarily pans out to the whole ring once more demonstrating
the mobility and versatility of the simulation as it pans round and
into the ring whilst pulling up and changing the data boxes. Finally,
the simulation once more pans down into the lingual tonsil and
observes the spread of Vir.
Found at doi:10.1371/journal.ppat.0030137.sv002 (83.9 MB AVI).
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